275.60
price down icon0.94%   -2.61
pre-market  Pre-market:  275.60  
loading
Bio-Rad Laboratories Inc. stock is currently priced at $275.60, with a 24-hour trading volume of 161.67K. It has seen a -0.94% decreased in the last 24 hours and a -19.20% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $280.3 pivot point. If it approaches the $275.3 support level, significant changes may occur.
Previous Close:
$278.21
Open:
$277.88
24h Volume:
161.67K
Market Cap:
$7.86B
Revenue:
$2.67B
Net Income/Loss:
$-637.32M
P/E Ratio:
-47.11
EPS:
-5.85
Net Cash Flow:
$218.26M
1W Performance:
-1.93%
1M Performance:
-19.20%
6M Performance:
-4.99%
1Y Performance:
-36.97%
1D Range:
Value
$272.35
$278.07
52W Range:
Value
$261.59
$473.50

Bio-Rad Laboratories Inc. Stock (BIO) Company Profile

Name
Name
Bio-Rad Laboratories Inc.
Name
Phone
510-724-7000
Name
Address
1000 Alfred Nobel Drive, Hercules
Name
Employee
8,000
Name
Twitter
@BioRadLifeSci
Name
Next Earnings Date
2024-05-07
Name
Latest SEC Filings
Name
BIO's Discussions on Twitter

Bio-Rad Laboratories Inc. Stock (BIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-07-23 Initiated UBS Buy
Jun-16-23 Initiated Wells Fargo Overweight
Dec-07-22 Initiated RBC Capital Mkts Outperform
Aug-25-22 Initiated Credit Suisse Outperform
Jan-28-22 Reiterated Citigroup Buy
Jan-08-20 Initiated Wells Fargo Overweight
Jan-07-20 Initiated Citigroup Buy
Oct-17-18 Initiated Goldman Buy
Sep-20-18 Initiated Morgan Stanley Equal-Weight
Feb-16-18 Downgrade CL King Buy → Neutral
Jul-13-17 Initiated Wells Fargo Outperform
Jun-28-17 Upgrade Deutsche Bank Hold → Buy
Jan-18-17 Initiated Deutsche Bank Hold
Oct-13-16 Initiated CL King Buy
May-06-15 Reiterated Jefferies Buy
Dec-18-09 Initiated Maxim Group Buy
Nov-06-09 Initiated Jefferies & Co Buy
Jul-17-09 Initiated Soleil Buy
Sep-26-07 Initiated Banc of America Sec Buy
Feb-23-07 Downgrade Robert W. Baird Outperform → Neutral
View All

Bio-Rad Laboratories Inc. Stock (BIO) Financials Data

Bio-Rad Laboratories Inc. (BIO) Revenue 2024

BIO reported a revenue (TTM) of $2.67 billion for the quarter ending December 31, 2023, a -4.67% decline year-over-year.
loading

Bio-Rad Laboratories Inc. (BIO) Net Income 2024

BIO net income (TTM) was -$637.32 million for the quarter ending December 31, 2023, a +82.43% increase year-over-year.
loading

Bio-Rad Laboratories Inc. (BIO) Cash Flow 2024

BIO recorded a free cash flow (TTM) of $218.26 million for the quarter ending December 31, 2023, a +171.84% increase year-over-year.
loading

Bio-Rad Laboratories Inc. (BIO) Earnings per Share 2024

BIO earnings per share (TTM) was -$21.49 for the quarter ending December 31, 2023, a +82.28% growth year-over-year.
loading

Bio-Rad Laboratories Inc. Stock (BIO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
ERNST TIMOTHY S
EVP, General Counsel & Sec
Feb 28 '24
Option Exercise
326.15
2,500
815,375
5,897
ERNST TIMOTHY S
EVP, General Counsel & Sec
Feb 28 '24
Sale
330.55
2,500
826,375
3,397
Crowley Michael
EVP, GBL Commercial Operations
Feb 27 '24
Option Exercise
215.98
3,000
647,940
9,942
Crowley Michael
EVP, GBL Commercial Operations
Feb 27 '24
Sale
336.00
3,000
1,008,000
6,942
WRIGHT DARA
EVP, President, CDG
Dec 16 '23
Option Exercise
0.00
502
0
2,001
WRIGHT DARA
EVP, President, CDG
Dec 12 '23
Sale
299.16
1,200
358,992
1,499
Crowley Michael
EVP, GBL Commercial Operations
Nov 28 '23
Sale
305.10
642
195,874
6,942
SCHWARTZ NORMAN D
Chairman, President, and CEO
Nov 01 '23
Option Exercise
133.57
66,000
8,815,760
380,300
Dahowski Diane
EVP, Global Supply Chain
Sep 04 '23
Option Exercise
0.00
600
0
12,155
COREY COLLEEN
EVP, Global Human Resources
Sep 04 '23
Option Exercise
0.00
600
0
17,431
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
medical_devices PHG
$20.72
price down icon 1.19%
medical_devices STE
$201.54
price down icon 0.62%
$310.50
price down icon 1.05%
medical_devices ZBH
$119.75
price down icon 1.17%
medical_devices EW
$88.01
price down icon 0.68%
$138.01
price up icon 0.10%
Cap:     |  Volume (24h):